Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices Q4 Revenues Rise 10 Percent; Profit Slides 60 Percent

NEW YORK, Feb. 8 (GenomeWeb News) - Molecular Devices yesterday reported a 10-percent increase in revenues as net income dropped 60 percent.

 

Revenues for the three months ended Dec. 31 increased 10 percent to $52.5 million. The company said that, eliminating the effects of foreign currency translation, actual revenues for the quarter grew 14 percent over the prior year.

  

R&D spending for the quarter dipped slightly to $6.3 million from $6.9 million in the year-ago period.

 

Fourth-quarter profit fell 60 percent to $5.7 million from $14.7 million year over year. This is because Molecular Devices included an $18-million gain on sale of equity for the fourth quarter of 2004.

 

Molecular Devices had around $28.9 million in cash and cash equivalents as of Dec. 31.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.